Order Article Reprints

Vita GL, Sframeli M, Licata N, Bitto A, Romeo S, Frisone F, Ciranni A, Pallio G, Mannino F, Aguennouz M, et al. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences. 2021; 11(1):115. https://doi.org/10.3390/brainsci11010115

Vita, Gian Luca, Maria Sframeli, Norma Licata, Alessandra Bitto, Sara Romeo, Francesca Frisone, Annamaria Ciranni, Giovanni Pallio, Federica Mannino, M’Hammed Aguennouz, and et al. 2021. "A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy" Brain Sciences 11, no. 1: 115. https://doi.org/10.3390/brainsci11010115

Vita, G. L., Sframeli, M., Licata, N., Bitto, A., Romeo, S., Frisone, F., Ciranni, A., Pallio, G., Mannino, F., Aguennouz, M., Rodolico, C., Squadrito, F., Toscano, A., Messina, S., & Vita, G. (2021). A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences, 11(1), 115. https://doi.org/10.3390/brainsci11010115